NDA 020671 · Sandoz
Hycamtin
Topotecan Hydrochloride · Injection
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Oct 8, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1996
May 28, 1996
Approved uses
4
Original approval plus efficacy supplements
Registered trials
477
118 Phase 3, 54 recruiting
FAERS reports
6,942
6,366 serious, 1,654 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: MYELOSUPPRESSION HYCAMTIN can cause severe myelosuppression. Administer first cycle only to patients with baseline neutrophil counts of greater than or equal to 1,500/mm 3 and platelet counts greater than or equal to 100,000/mm 3 . Monitor blood cell counts [see Warnings and Precautions ( 5.1 )] . WARNING: MYELOSUPPRESSION See full prescribing information for complete boxed warning. HYCAMTIN can cause severe myelosuppression. Administer first cycle only to patients with baseline neutrophil counts greater than or equal to 1,500/mm 3 and platelet counts greater than or equal to 100,000/mm 3 . Monitor blood cell counts ( 2.4 , 5.1 ).
What it is approved for
From the label in effect Jul 7, 2022.
HYCAMTIN for injection is a topoisomerase inhibitor indicated for treatment of: Patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy, as a single agent ( 1.1 ) Patients with small cell lung cancer (SCLC) platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy, as a single agent ( 1.2 ) Patients with Stage IV-B, recurrent, or persistent cervical cancer which is not amenable to curative treatment, in combination with cisplatin ( 1.3 ) 1.1 Ovarian Cancer HYCAMTIN ® for injection, as a single agent, is indicated for the treatment of patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy. 1.2 Small Cell Lung Cancer HYCAMTIN for injection, as a single agent, is indicated for the treatment of patients with small cell lung cancer (SCLC) with platinum-sensitive disease who progressed at least 60 days after initiation of first‑line chemotherapy. 1.3 Cervical Cancer HYCAMTIN for injection, in combination with cisplatin, is indicated for the treatment of patients with Stage IV-B, recurrent, or persistent cervical cancer not amenable to curative treatment.
Mechanism: Topoisomerase I relieves torsional strain in DNA by inducing reversible single-strand breaks. Topotecan binds to the topoisomerase I‑DNA complex and prevents re-ligation of these single-strand breaks. The cytotoxicity of topotecan is thought to be due to double-strand DNA damage produced during DNA synthesis, when replication enzymes interact with the ternary complex formed by topotecan, topoisomerase I, and DNA. Mammalian cells cannot efficiently repair these double-strand breaks.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 14, 2006 Supplement 14 · Efficacy · priority review LabelLetter
- Feb 26, 2003 Supplement 10 · Efficacy · priority review Other
- Nov 30, 1998 Supplement 4 · Efficacy LabelReviewLetter
- May 28, 1996 Original approval · Type 1 - New Molecular Entity · priority review Review
1 products under this application
- HYCAMTIN · TOPOTECAN HYDROCHLORIDE EQ 4MG BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Topotecan" as an intervention, any sponsor and status, largest first.
- Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal CancerPivotal-lookingCompleted
Gynecologic Oncology GroupResearch network
NCT00011986 · 4,312 participants · Start Jan 2001 · Primary completion Mar 2010
Drug: Paclitaxel; Carboplatin and 3 more · For: Primary Peritoneal Carcinoma; Stage III Ovarian Cancer; Stage IV Ovarian Cancer
Sites: Philadelphia, Pennsylvania
- A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian CancerPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07213804 · 1,630 participants (planned) · Start Oct 22, 2025 · Primary completion Nov 2028
Drug: Sofetabart Mipitecan; Paclitaxel and 6 more · For: Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms and 1 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Burbank, California · 264 sites in all
- AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian CancerPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07218809 · 1,100 participants (planned) · Start Dec 29, 2025 · Primary completion Nov 17, 2028
Drug: AZD5335; Mirvetuximab Soravtansine (MIRV) and 3 more · For: Epithelial Ovarian Cancer
Sites: Birmingham, Alabama; Little Rock, Arkansas; La Jolla, California · 299 sites in all
- Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian CancerPivotal-lookingCompleted
AGO Study GroupAcademic, hospital or other
NCT00102375 · 900 participants · Start Dec 1999
Drug: Topotecan · For: Ovarian Cancer
Sites: Aachen, Germany; Berlin, Germany; Dresden, Germany · 18 sites in all
- A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube CancerPivotal-lookingRecruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT06161025 · 860 participants (planned) · Start Feb 27, 2024 · Primary completion Feb 29, 2028
Drug: R-DXd; Paclitaxel and 2 more · For: Solid Cancer
Sites: Anchorage, Alaska; New Haven, Connecticut; Coral Gables, Florida · 167 sites in all
- Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerPivotal-lookingCompleted
NCIC Clinical Trials GroupResearch network
NCT00028743 · 819 participants · Start Aug 31, 2001 · Primary completion Mar 5, 2008
Drug: carboplatin; cisplatin and 2 more · For: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Sites: Calgary, Canada; Edmonton, Canada; Kelowna, Canada · 28 sites in all
- Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung CancerPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00049998 · 760 participants · Start Oct 2001 · Primary completion Apr 2004
Drug: topotecan · For: Non-Small-Cell Lung Cancer
Sites: Adelaide, Australia; Bedford Park, Australia; Melbourne, Australia · 114 sites in all
- Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive AdultsPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00043927 · 760 participants · Start Apr 2001 · Primary completion Jan 2004
Drug: topotecan/cisplatin; etoposide/cisplatin · For: Small Cell Lung Cancer
Sites: Hoover, Alabama; Chula Vista, California; Fountain Valley, California · 176 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- febrile neutropenia603
- anaemia580
- off label use575
- death573
- neutropenia559
- nausea477
- disease progression457
- thrombocytopenia453
- pyrexia449
- vomiting437
- product use in unapproved indication377
- fatigue337
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 138 |
| 2005 | 216 |
| 2006 | 123 |
| 2007 | 185 |
| 2008 | 159 |
| 2009 | 201 |
| 2010 | 238 |
| 2011 | 259 |
| 2012 | 313 |
| 2013 | 231 |
| 2014 | 301 |
| 2015 | 394 |
| 2016 | 397 |
| 2017 | 347 |
| 2018 | 408 |
| 2019 | 340 |
| 2020 | 473 |
| 2021 | 490 |
| 2022 | 430 |
| 2023 | 355 |
| 2024 | 344 |
| 2025 | 396 |
| 2026 | 203 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy.
Mountzios G, Sun L, Cho BC, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Multicenter Study
- Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
Moore KN, Angelergues A, Konecny GE, et al. · N Engl J Med 2023 · Clinical Trial, Phase III, Comparative Study
- Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Pujade-Lauraine E, Hilpert F, Weber B, et al. · J Clin Oncol 2014 · Clinical Trial, Phase III, Multicenter Study
- Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.
Vergote I, González-Martín A, Fujiwara K, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.
Moore KN, Oza AM, Colombo N, et al. · Ann Oncol 2021 · Clinical Trial, Phase III, Randomized Controlled Trial
- Improved survival with bevacizumab in advanced cervical cancer.
Tewari KS, Sill MW, Long HJ, et al. · N Engl J Med 2014 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.